Protocols: With Ninlaro sales suffering, Takeda launches huge multiple myeloma study; Medivir splitting, spinning R&D into a separate company
Takeda is rolling out a major new study involving multiple myeloma patients. Researchers are recruiting 5,000 patients to track their real world experience in being treated for the disease. Takeda bagged an FDA approval for Ninlaro last fall, but they’ve experienced disappointing sales so far. It’s also been blocked in Europe.
Sweden’s Medivir is pushing ahead with plans to divide the company into two independent entities, splitting its commercial operations and R&D portfolio. The move is expected to wrap up by the end of this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.